Menu
  • Join
  • Login
  • Contact
 

Search abstracts


IMPACT OF TACROLIMUS BLOOD CONCENTRATION ON CLINICAL OUTCOMES IN PATIENTS WITH MYASTHENIA GRAVIS

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: YAMAMOTO, Shota (Kyoto University Hospital, Department of Clinical Pharmacology and Therapeutics, Japan)
  • Co-author(s): Shota Yamamoto: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Atsushi Yonezawa: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Yuri Irachi: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Ikumi Hirozumi: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Yoshiki Katada: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Shunsaku Nakagawa: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Mitsuhiro Sugimoto: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Yuko Yoshida: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Tomohiro Omura: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Etsuro Nakanishi: Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Ryosuke Takahashi: Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Kazuo Matsubara: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  • Abstract:

    Background

    Myasthenia gravis (MG) is an autoimmune disease caused by autoantibodies acting primarily against acetylcholine receptors (AChRs), and needs the high-dose and long-continued therapy with prednisolone (PSL) for its treatment. In the clinical practice guideline for MG, it has been described that introduction of tacrolimus (TAC) at early..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses